On September 28, 2020 AQILION AB and Immunscape AB reported that it initiated a joint early project in oncology and autoimmune diseases in the spring of 2019 (Press release, Aqilion, SEP 28, 2020, View Source [SID1234567662]). The point of departure was to create a drug candidate that the parties would develop and test further in a joint feasibility study. The parties have now agreed to discontinue the project.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Collaborating with Immunscape has been highly rewarding and we continue to appreciate their expertise, from which we have gained great professional benefit. The feasibility study produced good technical results and new intangible assets, but external factors have led to declining interest in the continued commercial development of the project. We have therefore agreed to terminate our collaborative effort. It is extremely important for us to have the courage to start innovative projects, but also to have the courage to close those in which Aqilion cannot continue to create value, even if it is disappointing not to reach all the way to our goal," says Sarah Fredriksson, CEO of AQILION AB.

"We have appreciated the interactions with Aqilion and would like to thank them for their commitment to the project. Our collaboration with Aqilion has allowed us to advance our understanding of the drug targets in the project, which helps us to explore new uses of the compounds as potential treatments for certain cancers," says Lars Öhman, CEO of Immunscape AB.